Tenpoint Therapeutics Gains FDA Approval for Yuvezzi, a Combination Eye Drop to Treat Presbyopia

LONDON and SEATTLE—Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing treatments to improve vision in the aging eye, announced that the U.S. Food and Drug Administration (FDA) has approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop for the treatment of presbyopia in adults. According to the company, Yuvezzi is expected to be broadly commercially available in the U.S. in the second quarter of 2026.